[go: up one dir, main page]

MX2020009857A - Conjugados de interleucina-2 (il-2). - Google Patents

Conjugados de interleucina-2 (il-2).

Info

Publication number
MX2020009857A
MX2020009857A MX2020009857A MX2020009857A MX2020009857A MX 2020009857 A MX2020009857 A MX 2020009857A MX 2020009857 A MX2020009857 A MX 2020009857A MX 2020009857 A MX2020009857 A MX 2020009857A MX 2020009857 A MX2020009857 A MX 2020009857A
Authority
MX
Mexico
Prior art keywords
conjugates
interleukin
pharmaceutically acceptable
acceptable salt
conjugate
Prior art date
Application number
MX2020009857A
Other languages
English (en)
Inventor
Nicola Bisek
Thomas Knappe
Burkhardt Laufer
Harald Rau
Kennett Sprogøe
Original Assignee
Ascendis Pharma Oncology Div A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Oncology Div A/S filed Critical Ascendis Pharma Oncology Div A/S
Publication of MX2020009857A publication Critical patent/MX2020009857A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con los conjugados de IL-2, una sal farmacéuticamente aceptable de los mismos, las composiciones farmacéuticas que comprenden tales conjugado de IL- 2 o una sal farmacéuticamente aceptable del mismo y sus usos.
MX2020009857A 2018-03-28 2019-03-27 Conjugados de interleucina-2 (il-2). MX2020009857A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18164682 2018-03-28
PCT/EP2019/057709 WO2019185705A1 (en) 2018-03-28 2019-03-27 Il-2 conjugates

Publications (1)

Publication Number Publication Date
MX2020009857A true MX2020009857A (es) 2021-01-08

Family

ID=61832449

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020009857A MX2020009857A (es) 2018-03-28 2019-03-27 Conjugados de interleucina-2 (il-2).
MX2025007999A MX2025007999A (es) 2018-03-28 2020-09-22 Conjugados de interleucina-2 (il-2)

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025007999A MX2025007999A (es) 2018-03-28 2020-09-22 Conjugados de interleucina-2 (il-2)

Country Status (13)

Country Link
US (1) US20210024602A1 (es)
EP (1) EP3773680A1 (es)
JP (2) JP7490563B2 (es)
KR (2) KR20200139730A (es)
CN (2) CN119504973A (es)
AU (2) AU2019246389B2 (es)
BR (1) BR112020019639A2 (es)
CA (1) CA3093722A1 (es)
IL (3) IL277572B2 (es)
MA (1) MA52662A (es)
MX (2) MX2020009857A (es)
SG (1) SG11202007524QA (es)
WO (1) WO2019185705A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020002272A2 (pt) 2017-08-03 2020-07-28 Synthorx, Inc. conjugados de citocina para o tratamento de doenças autoimunes
TW202031284A (zh) 2018-11-08 2020-09-01 美商新索思股份有限公司 介白素10結合物及其用途
US20220054476A1 (en) 2019-01-04 2022-02-24 Ascendis Pharma Oncology Division A/S Sustained local drug levels for innate immune agonists
WO2020141221A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Conjugates of pattern recognition receptor agonists
US20220054478A1 (en) 2019-01-04 2022-02-24 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
US20200246467A1 (en) 2019-02-06 2020-08-06 Synthorx, Inc. Il-2 conjugates and methods of use thereof
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
US20220305136A1 (en) 2019-06-21 2022-09-29 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
BR112022003046A8 (pt) 2019-08-23 2024-02-06 Synthorx Inc Conjugado de il-15, seu método de preparo e seus usos, bem como composição farmacêutica e método in vitro de expansão de uma ou mais das populações de células t
EP4028060A1 (en) 2019-09-10 2022-07-20 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
CN121517534A (zh) * 2019-12-13 2026-02-13 辛德凯因股份有限公司 Il-2直向同源物及其使用方法
CN111018961B (zh) * 2019-12-17 2022-03-18 北京志道生物科技有限公司 白介素-2衍生物
AR121891A1 (es) 2020-04-22 2022-07-20 Merck Sharp & Dohme CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 bgᶜ Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO
EP4161956A1 (en) 2020-06-03 2023-04-12 Ascendis Pharma Oncology Division A/S Il-2 sequences and uses thereof
MX2023002047A (es) 2020-08-28 2023-03-15 Ascendis Pharma Oncology Div A/S Proteinas de interleucina 2 (il-2) glucosiladas y usos de las mismas.
US20240350589A1 (en) 2021-08-13 2024-10-24 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
AU2000202A (en) 2000-10-31 2002-05-15 Pr Pharmaceuticals Inc Methods and compositions for enhanced delivery of bioactive molecules
WO2003015697A2 (en) * 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
BR0214650A (pt) * 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
PT1620118E (pt) 2003-04-08 2014-10-16 Yeda Res & Dev Fármacos peguilados de modo reversível
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
JP5744369B2 (ja) * 2004-02-27 2015-07-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＩＬ１５−Ｒα用ＩＬ−１５結合部位およびアゴニスト／アンタゴニスト活性を有する特異的ＩＬ−１５突然変異体
JP2007527242A (ja) 2004-03-05 2007-09-27 カイロン コーポレーション 治療剤の患者耐容性を予測するためのインビトロ試験システム
JP4950022B2 (ja) * 2004-03-23 2012-06-13 コンプレックス バイオシステムズ ゲーエムベーハー 自壊性リンカーを有する高分子プロドラッグ
SG158186A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
CN101534643A (zh) 2006-09-15 2009-09-16 安佐制药股份有限公司 用于递送寡核苷酸的基于位阻酯的生物可降解连接体
PL2369005T3 (pl) 2007-06-21 2013-10-31 Univ Muenchen Tech Białka czynne biologicznie o zwiększonej stabilności in vivo i(lub) in vitro
TW200922624A (en) 2007-07-11 2009-06-01 Enzon Pharmaceuticals Inc Polymeric drug delivery system containing a multi-substituted aromatic moiety
ES2733355T3 (es) 2008-02-01 2019-11-28 Ascendis Pharma As Profármaco que comprende un enlazador autoescindible
DK2279007T3 (en) * 2008-04-29 2016-08-22 Ascendis Pharma Growth Disorders Div As Pegylated recombinant relations of human growth hormone
US20110105413A1 (en) 2008-05-23 2011-05-05 Enzon Pharmaceuticals, Inc. Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
EP2459220B1 (en) 2009-07-31 2020-09-09 Ascendis Pharma A/S Biodegradable polyethylene glycol based water-insoluble hydrogels
DK2889624T3 (en) 2009-08-10 2018-12-10 Ucl Business Plc Reversible covalent bonding of functional molecules
CU23734A1 (es) 2009-11-27 2011-11-15 Centro Inmunologia Molecular Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
CA2783296C (en) * 2009-12-15 2019-01-15 Ascendis Pharma As Growth hormone composition
US20120289571A1 (en) 2009-12-31 2012-11-15 Enzon Pharmaceuticals, Inc. Polymeric conjugates of aromatic amine containing compounds including releasable urea linker
US9561285B2 (en) * 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
EP2566335B1 (en) 2010-05-05 2016-06-29 Prolynx Llc Controlled release of active compounds from macromolecular conjugates
CN103025164B (zh) 2010-05-05 2017-03-08 普罗林科斯有限责任公司 从固体支撑物中药物的控制释放
MX357674B (es) 2010-05-21 2018-07-18 Xl Protein Gmbh Polipeptidos biosinteticos de espira aleatoria de prolina/alanina y sus usos.
WO2012002047A1 (ja) 2010-06-30 2012-01-05 Ｎｅｃソフト株式会社 属性判定方法、属性判定装置、プログラム、記録媒体および属性判定システム
DK2637694T3 (da) 2010-11-12 2021-06-07 Nektar Therapeutics KONJUGATER AF EN Il-2-ENHED OG EN POLYMER
MX340671B (es) 2011-02-10 2016-07-20 Roche Glycart Ag Polipeptidos interleuquina- 2 mutantes.
US20140243254A1 (en) 2011-08-12 2014-08-28 Ascendis Pharma A/S Polymeric Hyperbranched Carrier-Linked Prodrugs
CN103957930A (zh) * 2011-08-31 2014-07-30 国立大学法人三重大学 癌症治疗用疫苗制剂
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
MY177912A (en) 2012-10-11 2020-09-25 Ascendis Pharma Ophthalmology Div A/S Vegf neutralizing prodrugs for the treatment of ocular conditions
CN104781314B (zh) 2012-10-11 2017-11-14 阿森迪斯药物股份有限公司 水凝胶前药
EP2908845A1 (en) 2012-10-17 2015-08-26 Novo Nordisk Health Care AG Fatty acid acylated amino acids for growth hormone delivery
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
EP3134123B1 (en) * 2014-02-21 2021-02-17 Nektar Therapeutics (India) Pvt. Ltd. Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody
US11633487B2 (en) 2014-08-06 2023-04-25 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
SG11201700629TA (en) 2014-08-11 2017-02-27 Delinia Inc Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
LT3653227T (lt) * 2014-11-18 2021-03-25 Ascendis Pharma Endocrinology Division A/S Nauji polimeriniai hgh provaistai
WO2017118693A1 (en) * 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
KR20250044469A (ko) 2016-03-01 2025-03-31 아센디스 파마 본 디지즈 에이/에스 Pth 프로드럭
CN109789221B (zh) * 2016-09-29 2022-11-01 阿森迪斯药物骨疾病股份有限公司 控释pth的药物组合物
CU24483B1 (es) * 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
CN110891611B (zh) 2017-03-22 2024-03-29 阿森迪斯制药公司 水凝胶交联透明质酸前药组合物和方法
AU2018364114B2 (en) * 2017-11-08 2024-09-26 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
EP3773681A1 (en) * 2018-03-28 2021-02-17 Ascendis Pharma A/S Conjugates

Also Published As

Publication number Publication date
CA3093722A1 (en) 2019-10-03
CN111918665B (zh) 2024-11-26
MA52662A (fr) 2021-02-17
IL308797B1 (en) 2026-01-01
AU2019246389A1 (en) 2020-08-27
IL277572B1 (en) 2024-01-01
AU2019246389B2 (en) 2024-08-22
CN111918665A (zh) 2020-11-10
KR20250130705A (ko) 2025-09-02
IL308797A (en) 2024-01-01
MX2025007999A (es) 2025-08-01
IL277572B2 (en) 2024-05-01
JP2024073467A (ja) 2024-05-29
CN119504973A (zh) 2025-02-25
JP7490563B2 (ja) 2024-05-27
IL324874A (en) 2026-01-01
WO2019185705A1 (en) 2019-10-03
EP3773680A1 (en) 2021-02-17
AU2024259730A1 (en) 2024-12-05
JP2021519336A (ja) 2021-08-10
SG11202007524QA (en) 2020-09-29
IL277572A (en) 2020-11-30
KR20200139730A (ko) 2020-12-14
US20210024602A1 (en) 2021-01-28
RU2020135268A (ru) 2022-04-28
BR112020019639A2 (pt) 2021-01-05

Similar Documents

Publication Publication Date Title
MX2020009857A (es) Conjugados de interleucina-2 (il-2).
CL2021000405A1 (es) Moduladores de calpaínas y usos terapeuticos de los mismos (divisional sol. 201900793)
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
CO2021000043A2 (es) Degradadores selectivos del receptor de estrógeno
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
MX2020006150A (es) Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas.
CO2021011906A2 (es) Anticuerpos claudina 6 y usos de los mismos
MX2018015252A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX375286B (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2021005134A (es) Nuevos conjugados citostaticos con ligandos de integrina.
MX2021000377A (es) Degradadores selectivos del receptor de estrogeno.
MX378566B (es) Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
ECSP21030482A (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
CU20210077A7 (es) Extractos bacterianos estables como fármacos
DOP2020000160A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
MX2022000654A (es) Sistemas fluorescentes para imagenes biologicas y usos de los mismos.
MX2021000068A (es) Formas y composiciones farmaceuticas de ivosidenib.
CL2019003801A1 (es) Nuevas formulaciones orales de belinostato.
DOP2021000028A (es) Formulaciones de dendrímeros
AR132444A1 (es) Moduladores de nk3 y usos de los mismos
AR132445A1 (es) Moduladores de nk3 y usos de los mismos
CR20220587A (es) Formulaciones farmacéuticas
AR133577A1 (es) MODULADORES DE LA ACTIVIDAD DE TNF a Y USOS DE LOS MISMOS